Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma · Sponsor: The University of Hong Kong
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.
This description comes directly from the study's public registry record.
Lesley Lau, MPhil · +852 22554265 · lsk382@hku.hk
Iris Tang · +852 22554265 · iristwk@hku.hk
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, China | Not Yet Recruiting |
| The University of Hong Kong - Shenzhen Hospital | Shenzhen, China | Not Yet Recruiting |
| Pamela Youde Nethersole Eastern HospitalPamela Y | Chai Wan, Hong Kong | Not Yet Recruiting |
| Queen Mary Hospital, Department of Clinical Oncology | Hong Kong, Hong Kong | Not Yet Recruiting |
| The University of Hong Kong, Department of Obstetrics and Gynaecology | Hong Kong, Hong Kong | Recruiting |
| United Christian Hospital | Kwun Tong, Hong Kong | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07023484